[Skip to Content]
[Skip to Content Landing]
Views 473
Citations 0
News From the Food and Drug Administration
October 20, 2015

Easing Cancer Chemotherapy Effects

JAMA. 2015;314(15):1554. doi:10.1001/jama.2015.13011

The FDA approved a new drug last month to help prevent delayed-phase nausea and vomiting in patients undergoing cancer chemotherapy.

Rolapitant, marketed as Varubi, was approved for use by adults in combination with other antiemetic drugs (http://1.usa.gov/1EBmeA2). Nausea and vomiting are common among patients with cancer who receive chemotherapy, sometimes persisting for days following treatment. Delayed-phase nausea and vomiting is defined as occurring from 24 hours to up to 120 hours after the start of chemotherapy.

First Page Preview View Large
First page PDF preview
First page PDF preview